Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
2317 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Breast Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Breast Cancer - Pipeline Review, H1 2015', provides an overview of the Breast Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Breast Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 16 Breast Cancer Overview 17 Therapeutics Development 18 Breast Cancer - Therapeutics under Development by Companies 20 Breast Cancer - Therapeutics under Investigation by Universities/Institutes 51 Breast Cancer - Pipeline Products Glance 60 Breast Cancer - Products under Development by Companies 64 Breast Cancer - Products under Investigation by Universities/Institutes 111 Breast Cancer - Companies Involved in Therapeutics Development 122 Breast Cancer - Therapeutics Assessment 468 Drug Profiles 510 Breast Cancer - Recent Pipeline Updates 1716 Breast Cancer - Dormant Projects 2169 Breast Cancer - Discontinued Products 2208 Breast Cancer - Product Development Milestones 2219 Appendix 2231
List of Tables Number of Products under Development for Breast Cancer, H1 2015 103 Number of Products under Development for Breast Cancer - Comparative Analysis, H1 2015 104 Number of Products under Development by Companies, H1 2015 106 Number of Products under Development by Companies, H1 2015 (Contd..1) 107 Number of Products under Development by Companies, H1 2015 (Contd..2) 108 Number of Products under Development by Companies, H1 2015 (Contd..3) 109 Number of Products under Development by Companies, H1 2015 (Contd..4) 110 Number of Products under Development by Companies, H1 2015 (Contd..5) 111 Number of Products under Development by Companies, H1 2015 (Contd..6) 112 Number of Products under Development by Companies, H1 2015 (Contd..7) 113 Number of Products under Development by Companies, H1 2015 (Contd..8) 114 Number of Products under Development by Companies, H1 2015 (Contd..9) 115 Number of Products under Development by Companies, H1 2015 (Contd..10) 116 Number of Products under Development by Companies, H1 2015 (Contd..11) 117 Number of Products under Development by Companies, H1 2015 (Contd..12) 118 Number of Products under Development by Companies, H1 2015 (Contd..13) 119 Number of Products under Development by Companies, H1 2015 (Contd..14) 120 Number of Products under Development by Companies, H1 2015 (Contd..15) 121 Number of Products under Development by Companies, H1 2015 (Contd..16) 122 Number of Products under Development by Companies, H1 2015 (Contd..17) 123 Number of Products under Development by Companies, H1 2015 (Contd..18) 124 Number of Products under Development by Companies, H1 2015 (Contd..19) 125 Number of Products under Development by Companies, H1 2015 (Contd..20) 126 Number of Products under Development by Companies, H1 2015 (Contd..21) 127 Number of Products under Development by Companies, H1 2015 (Contd..22) 128 Number of Products under Development by Companies, H1 2015 (Contd..23) 129 Number of Products under Development by Companies, H1 2015 (Contd..24) 130 Number of Products under Development by Companies, H1 2015 (Contd..25) 131 Number of Products under Development by Companies, H1 2015 (Contd..26) 132 Number of Products under Development by Companies, H1 2015 (Contd..27) 133 Number of Products under Development by Companies, H1 2015 (Contd..28) 134 Number of Products under Development by Companies, H1 2015 (Contd..29) 135 Number of Products under Investigation by Universities/Institutes, H1 2015 137 Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 138 Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 139 Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 140 Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 141 Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 142 Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..6) 143 Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..7) 144 Comparative Analysis by Late Stage Development, H1 2015 145 Comparative Analysis by Clinical Stage Development, H1 2015 146 Comparative Analysis by Early Stage Development, H1 2015 147 Comparative Analysis by Unknown Stage Development, H1 2015 148 Products under Development by Companies, H1 2015 149 Products under Development by Companies, H1 2015 (Contd..1) 150 Products under Development by Companies, H1 2015 (Contd..2) 151 Products under Development by Companies, H1 2015 (Contd..3) 152 Products under Development by Companies, H1 2015 (Contd..4) 153 Products under Development by Companies, H1 2015 (Contd..5) 154 Products under Development by Companies, H1 2015 (Contd..6) 155 Products under Development by Companies, H1 2015 (Contd..7) 156 Products under Development by Companies, H1 2015 (Contd..8) 157 Products under Development by Companies, H1 2015 (Contd..9) 158 Products under Development by Companies, H1 2015 (Contd..10) 159 Products under Development by Companies, H1 2015 (Contd..11) 160 Products under Development by Companies, H1 2015 (Contd..12) 161 Products under Development by Companies, H1 2015 (Contd..13) 162 Products under Development by Companies, H1 2015 (Contd..14) 163 Products under Development by Companies, H1 2015 (Contd..15) 164 Products under Development by Companies, H1 2015 (Contd..16) 165 Products under Development by Companies, H1 2015 (Contd..17) 166 Products under Development by Companies, H1 2015 (Contd..18) 167 Products under Development by Companies, H1 2015 (Contd..19) 168 Products under Development by Companies, H1 2015 (Contd..20) 169 Products under Development by Companies, H1 2015 (Contd..21) 170 Products under Development by Companies, H1 2015 (Contd..22) 171 Products under Development by Companies, H1 2015 (Contd..23) 172 Products under Development by Companies, H1 2015 (Contd..24) 173 Products under Development by Companies, H1 2015 (Contd..25) 174 Products under Development by Companies, H1 2015 (Contd..26) 175 Products under Development by Companies, H1 2015 (Contd..27) 176 Products under Development by Companies, H1 2015 (Contd..28) 177 Products under Development by Companies, H1 2015 (Contd..29) 178 Products under Development by Companies, H1 2015 (Contd..30) 179 Products under Development by Companies, H1 2015 (Contd..31) 180 Products under Development by Companies, H1 2015 (Contd..32) 181 Products under Development by Companies, H1 2015 (Contd..33) 182 Products under Development by Companies, H1 2015 (Contd..34) 183 Products under Development by Companies, H1 2015 (Contd..35) 184 Products under Development by Companies, H1 2015 (Contd..36) 185 Products under Development by Companies, H1 2015 (Contd..37) 186 Products under Development by Companies, H1 2015 (Contd..38) 187 Products under Development by Companies, H1 2015 (Contd..39) 188 Products under Development by Companies, H1 2015 (Contd..40) 189 Products under Development by Companies, H1 2015 (Contd..41) 190 Products under Development by Companies, H1 2015 (Contd..42) 191 Products under Development by Companies, H1 2015 (Contd..43) 192 Products under Development by Companies, H1 2015 (Contd..44) 193 Products under Development by Companies, H1 2015 (Contd..45) 194 Products under Development by Companies, H1 2015 (Contd..46) 195 Products under Investigation by Universities/Institutes, H1 2015 196 Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 197 Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 198 Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 199 Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 200 Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 201 Products under Investigation by Universities/Institutes, H1 2015 (Contd..6) 202 Products under Investigation by Universities/Institutes, H1 2015 (Contd..7) 203 Products under Investigation by Universities/Institutes, H1 2015 (Contd..8) 204 Products under Investigation by Universities/Institutes, H1 2015 (Contd..9) 205 Products under Investigation by Universities/Institutes, H1 2015 (Contd..10) 206 Breast Cancer - Pipeline by 3-V Biosciences, Inc., H1 2015 207 Breast Cancer - Pipeline by A&G Pharmaceutical, Inc., H1 2015 208 Breast Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 209 Breast Cancer - Pipeline by AB Science, H1 2015 210 Breast Cancer - Pipeline by AbbVie Inc., H1 2015 211 Breast Cancer - Pipeline by AbGenomics International, Inc., H1 2015 212 Breast Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 213 Breast Cancer - Pipeline by Adaptimmune Limited, H1 2015 214 Breast Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2015 215 Breast Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H1 2015 216 Breast Cancer - Pipeline by Advaxis, Inc., H1 2015 217 Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015 218 Breast Cancer - Pipeline by Aegis Therapeutics, LLC, H1 2015 219 Breast Cancer - Pipeline by Aerpio Therapeutics, Inc., H1 2015 220 Breast Cancer - Pipeline by Aeterna Zentaris Inc., H1 2015 221 Breast Cancer - Pipeline by Affichem, H1 2015 222 Breast Cancer - Pipeline by Aileron Therapeutics, Inc., H1 2015 223 Breast Cancer - Pipeline by Alchemia Limited, H1 2015 224 Breast Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2015 225 Breast Cancer - Pipeline by Almac Discovery Ltd., H1 2015 226 Breast Cancer - Pipeline by AlphaMab Co., Ltd, H1 2015 227 Breast Cancer - Pipeline by AlphaVax, Inc., H1 2015 228 Breast Cancer - Pipeline by Amarna Therapeutics B.V., H1 2015 229 Breast Cancer - Pipeline by Ambrx, Inc., H1 2015 230 Breast Cancer - Pipeline by Amgen Inc., H1 2015 231 Breast Cancer - Pipeline by Ampio Pharmaceuticals, Inc., H1 2015 232
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.